• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

aXichem

2.05 SEK

-4.21 %

Less than 1K followers

AXIC A

First North Stockholm

Chemicals

Basic Materials

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-4.21 %
+57.09 %
+41.38 %
-4.84 %
-0.24 %
-28.79 %
-69.77 %
-92.33 %
-87.77 %

aXichem is active in industrial biotechnology. The company develops, patents and markets industrial chemicals. The company works mainly with Phenylcapsaicin, a natural analogue synthetic capsaicin with applications in a variety of areas, such as in the marine sector, among pest control in forestry and agriculture, and among individual pharmaceutical work areas. Operations are conducted on a global level, with headquarters in Malmö.

Read more
Market cap
138.84M SEK
Turnover
199.71K SEK
Revenue
18.45M
EBIT %
-94.8 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
27.8
2026

Interim report Q2'26

26.11
2026

Interim report Q3'26

25.2
2027

Annual report '26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release10.11.2022, 07.47

Redeye: aXichem - Essential approvals ahead

aXichem
Regulatory press release27.10.2021, 08.30

aXichem AB: aXichem secures production capacity for phenylcapsaicin, corresponding to volumes of up to 100 tons of aXiphen-feed, for the upcoming six to nine months

aXichem
Regulatory press release04.10.2021, 09.00

aXichem AB: aXichem exhibits at Vitafoods Europe 2021 in Geneva, and launches a new website presenting the unique product aXivite

aXichem

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release13.09.2021, 09.00

aXichem AB: aXichem exhibits at Vitafoods Europe 2021 in Geneva, presenting its innovative product aXivite, with proven significant effect in decrease of body fat

aXichem
Regulatory press release07.09.2021, 08.50

Redeye: aXichem - Entering the Commercial Phase

aXichem
Regulatory press release12.04.2021, 15.30

aXichem AB: aXichem's product aXivite[®] is the active ingredient in a new pre-workout drink launched on the Spanish market

aXichem
Regulatory press release24.11.2020, 12.00

aXichem AB: aXichem signs agreement with BART regarding distribution and sales of aXivite® in Poland

aXichem
Regulatory press release05.10.2020, 12.20

aXichem AB: aXichem's natural analogue capsaicin, aXivite, is a key ingredient in new consumer product, for histamine intolerance, to be launched in the U.S. market

aXichem
Regulatory press release05.10.2020, 12.00

aXichem AB: aXichem announces first consumer product for weight loss, with aXivite as an active ingredient, to be launched in the French market by Sarl Myterrapy

aXichem
Regulatory press release25.09.2020, 18.30

aXichem AB: aXichem presents its natural analogue capsaicin aXivite, together with new marketing material, in series of webinars

aXichem
Regulatory press release20.07.2020, 12.30

aXichem AB: aXichem obtains order from Actives & Co for aXivite, to be used in product development project for the French market

aXichem
Regulatory press release14.07.2020, 13.00

aXichem AB: aXichem signs distribution agreement with Berg Nutrition for sales and distribution of aXivite® to the ingredients market in the U.S. and Canada

aXichem
Regulatory press release30.03.2020, 16.00

aXichem AB: aXichem signs agreement with Actives & Co for sales and distribution of aXivite® in France

aXichem
Regulatory press release03.03.2020, 10.40

aXichem AB: aXichem signs distribution agreement with Tecom Ingredients for sales and distribution of aXivite® in Spain

aXichem
Regulatory press release25.02.2019, 10.47

aXichem AB: aXichem and Canadian based Iovate sign Letter of Intent regarding development and commercialization of aXivite, as ingredient in weight management supplement

aXichem
Regulatory press release12.10.2018, 12.45

aXichem launches aXivite®, a new brand for nutraceuticals

aXichem